Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
NexThera Submits IND Application for NT-101 for Wet AMD
NexThera has officially submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, an innovative non-invasive eye drop treatment targeting wet age-related macular degeneration (wet AMD). Proprietary Delivery Platform: Advancing Treatment…
Funding Boost for PulseMedica’s Eye Floater Technology
PulseMedica has successfully raised a total of $12 million in their recent pre-Series A financing round, marking a significant milestone in their pursuit of innovative eye floater diagnostic and treatment technologies. Accelerating Clinical Validation and Expansion Efforts This funding round…
FDA Clears Enhanced SPECTRALIS® OCTA Module by Heidelberg
Heidelberg Engineering announced the FDA clearance of its upgraded SPECTRALIS® OCTA Module featuring SHIFT technology. This advancement promises to significantly reduce acquisition time by 50%, marking a pivotal development in clinical efficiency and diagnostic precision within ophthalmology. Enhancing Clinical Utility…
Sydnexis Appoints Perry J. Sternberg as CEO
Sydnexis, Inc., a pioneering biopharmaceutical company dedicated to addressing pediatric myopia progression, has appointed Perry J. Sternberg as its Chief Executive Officer and as a member of its Board of Directors. Sternberg, a seasoned pharmaceutical and biotech executive with over…
Merck Completes Acquisition of EyeBio
Merck, known as MSD outside of the United States and Canada, announced the successful completion of its acquisition of Eyebiotech Limited (EyeBio), marking EyeBio as a fully owned subsidiary of Merck. “The EyeBio acquisition further diversifies our late-stage pipeline with…
Outlook Therapeutics Receives UK Approval of Lytenava for AMD
Outlook Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (AMD) in the UK. Lytenava is the first and only authorized…
Beacon Therapeutics Propels Gene Therapy with $170M Funding
Beacon Therapeutics has successfully raised $170 million in Series B funding, marking a significant step forward in advancing its portfolio of ophthalmic gene therapies. The funds are earmarked to support the ongoing clinical development of Beacon’s lead candidate, AGTC-501, designed…
Alcon Finalizes Acquisition of BELKIN Vision
Alcon has finalized its acquisition of BELKIN Vision, marking a significant expansion of its glaucoma treatment offerings. The acquisition, valued at $81M upfront, with potential additional payments up to $385M contingent on sales milestones, includes BELKIN Vision’s innovative Direct Selective…
Novel AI Boosts Geographic Atrophy Clinical Trial Efficiency
A new artificial intelligence (AI) system developed by researchers from UCL and Moorfields Eye Hospital could potentially revolutionize the recruitment process for clinical trials aimed at treating Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) that…
NVISION Eye Centers Partners with Parkhurst NuVision
NVISION Eye Centers, a prominent provider of eye care services nationwide, announced a strategic collaboration with Parkhurst NuVision of San Antonio, Texas, through its subsidiary NVision Clinical Research, LLC. This partnership aims to advance clinical trials in ophthalmology drug development,…